Assembly biosciences to introduce new small molecule liver-focused interferon-Α receptor agonist research program in webcast on july 26, 2022

South san francisco, calif., june 21, 2022 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis b virus (hbv) and other viral diseases, plans to host a webcast on tuesday, july 26, 2022 from 1:30-2:30 pm pt/4:30-5:30 pm et to introduce its new research program advancing a novel, small molecule interferon-Α receptor (ifnar) agonist designed to selectively activate the interferon-Α pathway within the liver and offer the convenience of oral dosing.
ASMB Ratings Summary
ASMB Quant Ranking